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Assembly of a p–p stack of ligands in the
binding site of an acetylcholine-binding protein
Mariano Stornaiuolo1, Gerdien E. De Kloe2, Prakash Rucktooa1, Alexander Fish1, Rene´ van Elk3,
Ewald S. Edink2, Daniel Bertrand4, August B. Smit3, Iwan J. P. de Esch2 & Titia K. Sixma1
Acetylcholine-binding protein is a water-soluble homologue of the extracellular ligand-
binding domain of cys-loop receptors. It is used as a structurally accessible prototype for
studying ligand binding to these pharmaceutically important pentameric ion channels, in
particular to nicotinic acetylcholine receptors, due to conserved binding site residues present
at the interface between two subunits. Here we report that an aromatic conjugated small
molecule binds acetylcholine-binding protein in an ordered p–p stack of three identical
molecules per binding site, two parallel and one antiparallel. Acetylcholine-binding protein
stabilizes the assembly of the stack by aromatic contacts. Thanks to the plasticity of its
ligand-binding site, acetylcholine-binding protein can accommodate the formation of
aromatic stacks of different size by simple loop repositioning and minimal adjustment of the
interactions. This type of supramolecular binding provides a novel paradigm in drug design.
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S
creening compound libraries for biologically active mole-
cules results in hit structures considered to be interesting
starting points for drug design. Although it is often assumed
that a single small drug molecule interacts with one protein-
binding site, compounds binding to target proteins with higher
stoichiometry can be found during library screening1. Here, we
show an unexpected ligand interaction where three identical
molecules interact within a single binding site. The binding of
preorganized and/or in situ-organizing small binder molecules
was shown to happen on the surface of proteins but examples of
supramolecular assembly happening at the canonical-binding site
of a target are still rare2,3. Recently two molecules of the IRE1
inhibitor quercetin were found binding at the dimer interface of
the target and proved to induce its dimerization4 (PDB: 3LJ0). An
example of ligand supramolecular assembly was described also for
a ﬂavine-binding enzyme in complex with the cofactors FMN and
NADH at the surface of the protein5 (PDB: 2VZH, 2VZJ).
Cys-loop receptors are important ligand-gated ion channels in
the central and peripheral nervous systems6–10. Members
include the nicotinic acetylcholine receptors (nAChR), GABAA
receptors, 5HT3 serotonin and glycine receptors, and all
Table 1 | Chemical formula, numbering and IUPAC name of
the fragments.
2 1-Amino-3-(2-pyridyl)isoquinoline
3 1-Amino-3-(3-pyridyl)isoquinoline
4 6-Amino-2,20-bipyridine
5 4-(4-Methylpiperazin-1-yl)-6-phenylpyrimidin-2-amine
6 2-(1-Methylimidazol-2-yl)-4,6-dipyridine
IUPAC, International Union of Pure and Applied Chemistry.
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Figure 1 | VUF9432 binds as a triple stack to Ac-AChBP. (a) Chemical structure of VUF9432 (carbon atoms in yellow, nitrogen atoms in blue).
(b) Displacement of radio-labelled epibatidine (EPI) by VUF9432 (red curves), nicotine (blue curves) and acetylcholine (green curves) on Ac-AChBP
(puriﬁed proteins). Data are the mean±s.e.m. of three experiments and are reported below the panel. (c) Side and bottom side view of Ac-AChBP-
VUF9432 complex structure, showing VUF9432 molecules (yellow sticks) in the ﬁve binding sites. (d) Protomer–protomer interfaces (surface
representation) of Ac-AChBP-VUF9432 complex. Principal side is depicted in silver and complementary side in sand colours. Ligand-binding site are shown
in transparency. (e) Electron density map displaying VUF9432 molecules in the ligand-binding site formed by subunit A and B (experimental density
contoured at 1 s), different orientation of the stacking molecules are shown together with the nomenclature used to distinguish the three molecules
in the text. Intermolecular distances and angles are depicted as lines between the planes. dist, distal; med, medial; prox, proximal.
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important pharmacological targets for various diseases and
conditions10. nAChRs are targets for the endogenous
neurotransmitter acetylcholine and for a series of compounds
aimed at the treatment of cognitive decline in Alzheimer’s disease,
certain forms of epilepsy11 or nicotine addiction12.
In the homo- or heteropentameric ion channels of the cys-loop
receptor family, an extracellular ligand-binding site, is located
at the interface between a ‘principal’ and a ‘complementary’
subunit, each of which contributes three loops (A–C and D–F,
respectively) to the binding6–8,13. Agonist binding triggers
conformational changes in cys-loop receptors and leads to
opening of the channel and a ﬂux of ions through the channel
pore14. Ligand-binding sites in cys-loop receptors are highly
plastic, allowing binding of various molecules ranging from small
neurotransmitters all the way to large peptide neurotoxins, such
as conotoxins and snake toxin6–10. Flexibility for different-sized
ligands is generated by the positioning of loop C that contributes
two conserved tyrosines and a vicinal disulphide bridge to the
ligand-binding site.
Most high-resolution structural information on cys-loop
receptor–ligand interactions is available from a molluscan
acetylcholine-binding protein (AChBP)15–18. AChBP structurally
resembles the ligand-binding domains of cys-loop receptors, but
lacks a transmembrane domain16. Their ligand-binding site
resembles the a7 subtype of the nAChRs most (20–24% sequence
identity) and their high-resolution crystal structures16–23 reveal a
structural fold closely related to cys-loop receptors as well as to their
bacterial homologs24–29.
Here we show that AChBP binds an ordered aromatic p–p
stack of three identical ligands. The high-resolution X-ray crystal
structure of this molecule in complex with Aplysia californica
(Ac)-AChBP reveals a new example of protein–ligand interaction
controlled by supramolecular ligand assembly. The nature of the
binding mode, the analysis of protein residues contributing to the
stabilization of the stack and the kinetics of the binding events
are described. Finally, we identify acridine orange (AO) as a
ligand with similar binding that could potentially be used as
competitive inhibitor for a7 nAChR.
Results
Identiﬁcation of VUF9432. A fragment30,31 screening assay
using online ﬂuorescence enhancement led to the identiﬁcation
of fragments 2–6 (Table 1) as hits for AChBP (refs 32,33).
In a subsequent analogue screening, VUF9432 (1),
(IUPAC name: 4,6-dimethyl-N-(3-(pyridin-2-yl)isoquinoline-
1-yl)-pyrimidine-2-carboximidamide) (Fig. 1a) was shown to
have micromolar afﬁnity for AChBP. VUF9432 was originally
synthesized as a copper-dependent antimycoplasmal agent active
against Mycoplasma gallisepticum proliferation and later
identiﬁed in a screen as ligand for adenosine A3 receptors34.
Binding afﬁnities of VUF9432 for Ac-AChBP and a7 nAChR
were measured in a radioligand displacement assay with [3H]
epibatidine and [3H] methyllycaconitine (MLA) as displaceable
ligands for AChBPs (Fig. 1b) and a7 nAChR (Supplementary Fig.
S1), respectively. VUF9432 behaves as competitive binder for
AChBP, showing a pKi value of 4.96±0.03 for Ac-AChBP. The
compound also displays some binding to a7 nAChR (pKi around
ﬁve) but the radioligand is not fully displaced at the highest
concentration tested, possibly due to low solubility of the
compound under the assay conditions.
In contrast to typical nAChR targeting molecules, VUF9432
lacks the canonical cation center involved in cation-p interactions
with aromatic residues in the binding site13,14. The binding mode,
interaction of VUF9432 to Ac-AChBP, was investigated by
cocrystallization trials and X-ray analysis.
VUF9432 binds AChBP in a triple stacked conﬁguration.
The 2.4-Å crystal structure of the complex between Ac-AChBP
and VUF9432 revealed the unexpected presence of three
VUF9432 molecules in four out of the ﬁve ligand-binding sites in
the pentamer (the ﬁfth site is discussed separately below)
(Fig. 1c,d). Careful reﬁnement of the protein and the asymmetric
shape of the VUF9432 molecule allowed the unambiguous ﬁtting
into the electron densities (Fig. 1e and Supplementary Fig. S2),
resulting in a reﬁned structure with R¼ 21%/Rfree¼ 25% and
excellent stereochemistry (Table 2).
Within each ligand-binding site, the three conjugated mole-
cules of VUF9432 stack on each other (Fig. 1e) in a ﬂat planar
conﬁguration. The three molecules are organized in a columnar
stack, with an off-centred parallel displaced geometry. The distal
molecule of VUF9432, closest to the C-loop and the medial one
(Fig. 1e) are identically oriented with the pyrimidine rings
pointing towards the inner part of the ligand-binding site,
whereas the proximal molecule is twofold rotated relative to the
other VUF9432 molecules. The distance between the medial
molecule and the proximal and distal ones are 3.5 and 3.6 Å,
respectively, consistent with previously measured p–p stacking
distances between aromatic molecules35. The angle between the
planes is at most 3.8±0.8 and 6.2±2.1, due to slight tilting of
the medial and proximal molecules towards the distal one,
respectively, conﬁrming the almost perfectly parallel displaced
orientation (Fig. 1e). The proximal and distal copies of the
molecule occupy slightly variable tilt angles within these planes,
and hence have somewhat higher average B factors (58.4±10.23,
60.28±10.16 and 74.45±11.8 Å2 for the medial, proximal and
distal copy of VUF9432, respectively). Nevertheless it is clear that
all three sites are fully occupied and the excellent quality of the
electron density of the C-loop indicates full occupancy of these
ligands.
Table 2 | Data collection and reﬁnement statistics.
AChBP-VUF9432
Data collection PX1 (SLS)
Space group P21
Cell dimensions
a, b, c (Å) 80.73, 78.33, 106.53
a, b, g () 90.00, 102.67, 90.00
Resolution (Å) 43.30–2.4 (2.53–2.4)*
Rmerge 12.9 (76.1)
I/sI 5.9 (1.8)
Completeness (%) 93.0 (92.6)
Redundancy 2.4
Reﬁnement
Resolution (Å) 41.26–2.4 (2.53–2.4)
No. of reﬂections 44,879
Rwork/Rfree 0.21/0.25
No. of atoms
Protein 8,188
Ligand/ion 384
Water 129
B-factors
Protein 36.80
Ligand/ion 63.48
Water 27.41
R.m.s deviations
Bond lengths (Å) 0.009
Bond angles () 1.315
*Highest resolution shell is shown in parenthesis
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The stack of aromatic VUF9432 molecules is held in place like
a pile of books, at one end by the stacking of well-conserved
principal face residue Y186 (Fig. 2a), which has an off-centred
displaced parallel p–p interaction with the distal molecule,
tilted at 12.3±2.4. At the other end the stack is positioned
through van der Waals interactions with complementary side
residues Q55 and M114. The side chain of I116 is positioned
towards the stack, but does not interact with the proximal
molecule.
Aromatic groups on the principal (Y91, W145, Y193) and
complementary faces (Y53) stabilize the sides of the stack of
ligands via edge-to-face interactions, establishing T-shaped
aromatic contacts with the molecules (Fig. 2a). Finally, the
F-loop D162 and the vicinal disulphide in the C-loop also interact
with the sides of the stacked VUF9432 molecules.
Taken together, the three stacked molecules of VUF9432
occupy a large volume and bury a substantial surface area in
AChBP (959.9±4.8 Å2) comparable with the area buried by
conotoxins IMI20 (PDB:2C9T) and PnIA19 (PDB:2BR8) (1164Å2
and 1468Å2, respectively). However, the position of VUF9432 in
the binding site is different, as can be seen in Fig. 2b. The
space occupied by the conotoxins is above the midline of the
pentamer, away from the transmembrane domain in the cys-loop
receptors, whereas the VUF9432 molecules are placed lower,
close to the membrane, not far from the binding site for MLA
(ref. 36). However, MLA (PDB:2BYR) is in a different site closer
to the ﬁve-fold axis than VUF9432, which uses a lower,
more external cavity (Fig. 2b). It does not address the so-called
‘lobeline pocket’ and Y91 is in the g-conformation, interacting
with S14437. The combination of this novel position and slightly
smaller buried surface area result in a C-loop position that is
similar to that for the conotoxins, in its most open state
(Supplementary Fig. S3).
In one of the ﬁve ligand-binding sites only two molecules of
VUF9432 are bound, positioned in parallel manner, similarly to
the medial and the distal copy in the other ligand-binding sites
(Fig. 3a,b). This state is most likely stabilized by crystal contacts
(Fig. 3f). Although the double stack is tilted 15relative to the
triple stack in the other binding sites (Fig. 3c), the direct contacts
are retained. Thus, the stack is upheld by Y186 at one end and
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Figure 2 | Details of VUF9432 binding to Ac-AChBP. (a) Ball-and-stick representation showing Ac-AChBP residues on principal and complementary
subunits interacting with VUF9432 (colours as in Fig. 1). The triple stack is held up like a row of books by Y186, Q55 and M114. Edge interactions with
aromatic residues, D162 and the vicinal disulphide are indicated. (b) Protomer–protomer interfaces of VUF9432-Ac-AChBP structure illustrating how
VUF9432 (surface, yellow) is occupying a lower part of the ligand-binding site if compared with the toxin IMI (surface, grey), PnIA (surface, grey) and MLA
(surface, grey). (c) Comparison of C-loop opening in AChBP- nicotine (cyan), AChBP-PnIA (red), AChBP-IMI (green) and AChBP-VUF9432 (yellow)
complex. Position assumed by the C-loop after VUF9432 binding resembles that in conotoxins. (d) Comparison of binding modes of Imidacloprid
(magenta) and VUF9432 (yellow) to AChBP showing the two ligands establishing similar interactions with the ligand-binding site. Repositioning of
the C-loop provides the space for either one, two or three ﬂat aromatic moieties.
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M114 and Q55 at the other end with similar side interactions
(Fig. 3d). The major difference for this binding site is caused by
the loop C position, which in this case is in an intermediate open
state, similar to that found for ligands such as tubocurarine38
(PDB:2XYT) and a-cobratoxin39 (PDB:1YI5) (Fig. 3e).
Interestingly, these contacts resemble those described for
the pentameric ring of imidacloprid40,41. In that case, the ﬂat
aromatic imidazolinic part of the molecule is held in place by face
to face stacking with Y186 and upheld by van der Waals contacts
with M114. A H-bond connects the Q55 to an oxygen of the nitro
group of imidacloprid (Fig. 2d), now held in place by a maximally
closed C-loop.
Here, we show that the binding site of AChBP provides space
for either one, as in imidacloprid, two or three ﬂat aromatic
moieties as seen here for VUF9432, all with similar contacts.
This remarkable plasticity is organized primarily by repositioning
of the C-loop (Fig. 2d).
Ligand stacking promoted by aromaticity and planarity.
To exclude that the unusual conﬁguration of these ligands is a
crystallographic artifact, we analysed the binding in several ways.
First we conﬁrmed the VUF9432 binding to the ligand-binding
site, by mutating interacting amino acids. Mutation of either
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Figure 3 | AChBP can accommodate a double stack of VUF9432. (a) Side view of Ac-AChBP-VUF9432 complex structure, showing two VUF9432
molecules (yellow sticks) in the binding site formed by subunit B (sand) and C (cyan). (b) Electron density map displaying VUF9432 molecules in the
ligand-binding site formed by subunit B and C (experimental density contoured at 1 s). (c) Superposition of the four ligand binds site binding triple stacks of
VUF9432 (grey cartoon and sticks) and the one binding the double stack of molecule (yellow cartoon and sticks), showing the movement of the
Y186 to accommodate the third molecule of the stack. (d) Ball-and-stick representation showing AChBP residues on principal and complementary
subunits interacting with the double stack of VUF9432 (colours as in a). (e) Comparison of C-loop opening in AChBP-tubocurarine (Tub, green),
AChBP-a-cobratoxin (Cbtx, red), AChBP-VUF9432 (the shown C-loop is the one of the ligand-binding site containing two copies of the stack, yellow)
complex. Position assumed by the C-loop after VUF9432 binding resembles that in cobratoxin. (f) Interaction of an AChBP-VUF9432 molecule with the
symmetry-related molecule that form intermolecular contacts. The open C-loop of subunit B contacts the F-loop of a symmetry-related molecules.
The bound VUF9432 molecules are shown in ball and sticks.
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Y186 or Y193 to alanine resulted in the loss of afﬁnity for
VUF9432 (Supplementary Fig. S4), conﬁrming, also in solution,
the binding to the canonical pocket.
We then tested the stoichiometry of VUF9432 binding to
Ac-AChBP in solution, using equilibrium titration. Binding
was analysed by the change in the ﬂuorescence emission of W145
of AChBP, which correlates with the binding of agonists or
antagonists42. Titration of nicotine binding at high protein
concentrations showed that the ﬂuorescence quenching reaches a
plateau at the stoichiometric ratio ligand/AChBP close to one
nicotine molecule bound per protomer (Fig. 4b,c). In contrast the
titration proﬁle of VUF9432 binding does not saturate until a
stoichiometry of three ligands per protomer is reached (Fig. 4d,e),
conﬁrming the crystallographic data.
We wondered what properties of VUF9432 are necessary for
the supramolecular binding. Conformational analysis in the gas
phase (Supplementary Fig. S5a) shows that VUF9432 can adopt a
series of relatively planar conformations, with minimal rotational
freedom of the pyridine ring and of the amidine bond. In the
structure a conformation is selected where the pyridine,
isoquinoline and pyrimidine rings are coplanar stabilized by a
hydrogen bond between the amidine N2 and the isoquinolinic N4.
We then analysed the original fragment hits for their ligand-
binding stoichiometries using ﬂuorescence quenching. Afﬁnity
of these fragments for Ac-AChBP was relatively weak
(Supplementary Fig. 6, numbers presented as mean pKi in
Fig. 4f–k), which meant that we could only use a relative small
excess of Ac-AChBP in these experiments. Nevertheless, we
could clearly observe that several fragments retain the ability to
bind in a three-to-one ratio.
Derivatives,VUF6141 (2) and VUF5954 (3) (Fig. 4g,h), that lack
the pyrimidine ring show similar afﬁnity to Ac-AChBP compared
with VUF9432, in line with the lack of interaction
with Ac-AChBP for this moiety. In computational analysis,
both compounds are able to adopt a planar conﬁguration
(Supplementary Fig. S5b,c), especially compound 2, where the
planar conﬁguration is the most stable, thanks to the N in position
6 of the pyridine, that prevents clashing between the hydrogen
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Figure 4 | Aromaticity and planarity determine multiple ligand binding to AChBP. (a) Comparison of afﬁnity of Ac-AChBP for VUF9432 (red curve) and
nicotine (black curve) measured with tryptophan ﬂuorescence quenching. Titration of binding sites for nicotine (b,c) and VUF9432 (d,e) on Ac-AChBP by
ﬂuorescence quenching. Ac-AChBP at 20mM binding sites was titrated with incremental quantities of ligand. Fluorescence excitation was at 280 nm. Full
emission spectra were recorded and maxima were measured over the range 335–345 nm (b,d) and plotted versus the nicotine/AChBP (c, black dots) or
VUF9432/AChBP (e, red dots) stoichiometric ratio. A straight line was ﬁt through the plateau points (grey line) as described in the methods section. (f–k)
Titration of binding sites for the VUF9432 and analogues on Ac-AChBP by ﬂuorescence quenching. Afﬁnity for AChBP (mean±s.e.m. measured with
radiodisplacement assay) and structure of the ligands (colours as in ﬁgure 1) are indicated. AChBP at 20mM was titrated with incremental quantities of
ligands as described above (ﬂuorescence maxima plotted as in c).
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atoms of the isoquinolinic and the pyridine rings (Supplementary
Fig. S5b,c). Equilibrium ﬂuorescence titration clearly indicates that
Ac-AChBP can bind multiple copies of ligand 2 and 3 per binding
site (Fig. 4g,h).
Interestingly, supramolecular binding was also seen for the
bi-pyrimidinic compound VUF11370 (4) (Fig. 4i) showing
that different aromatic planar molecules can self-assemble in
Ac-AChBP. As seen for 2, compound 4 prefers the planar
conformation (Supplementary Fig. S5d). In compound VUF10460
(5), a piperazine moiety is present. As seen for nicotine (Fig. 4c)
and many other canonical AChBP ligands42, this compound
induces less ﬂuorescence quenching after binding to AChBP.
Equilibrium ﬂuorescence titration indicates the stoichiometry is
changed to 1:1, although the afﬁnity for the receptor was
maintained (Fig. 4j). This molecule is not fully aromatic resulting
in non-planarity of the piperazine moiety (Supplementary Fig. S5e),
which most likely prevents the stacking observed in compounds
1–4. Moreover, the compound is slightly basic, which could allow a
cation-p interaction and an alternative binding mode.
The presence of an imidazolinic moiety like in compound
VUF14476 (6) could result in a loss of the binding of multiple
copies (Fig. 4k). In compound 6, the methyl group attached to
the imidazole ring is located at the centre of the molecule
(Supplementary Fig. S5f), possibly preventing the formation of
stacked molecules. Although there are two methyl groups present
on the pyrimidine ring of VUF9432, these are at the edge of the
molecule. The slight displacement of the molecules in the stacks
may just be enough to ensure the absence of clashes between the
hydrogen atoms of the methyl present on the distal and the medial
molecules, when located at the edge of the molecule. Even
assembling in a similar displaced conﬁguration, the clashes
between the hydrogen atoms of the methyl group of 6 could
probably not be avoided, explaining the one to one stoichiometry to
AChBP.
Binding of VUF9432 molecules occurs in steps. An interesting
question is whether the three molecules bind as a ‘package’ or
whether they bind sequentially. For this we ﬁrst analysed the shape
of the binding curves of the three molecules in VUF9432 and
derivatives 2–4 (Fig. 4a,g–i), some of which may be non-linear.
This non-linearity could reﬂect differences in afﬁnities for the three
VUF9432 sites, resulting in differently shaped binding curves.
Alternatively, the effect of binding of the three individual molecules
could have differential effects on the tryptophan quenching. One
could even imagine that a stack of more than one ligand will
receive increased levels of resonance energy transferred from
remote aromatic residues, otherwise unaffected by the binding of a
single molecule. It will not be trivial to uncouple these possibilities,
but it seems likely that the binding event is not a single-step
transition of a single package of three ligands into the binding site.
To analyse the binding process in more detail, we used stopped-
ﬂow kinetic studies to monitor this assembly process (Fig. 5).
Titration of nicotine shows simple association to Ac-AChBP
(Fig. 5a)42 that can be ﬁtted with a one-step binding model
(Fig. 5d). In contrast, the binding proﬁle of VUF9432 cannot be
ﬁtted with a simple model (Fig. 5b,c). In practice a two-step ﬁtting
of the binding is sufﬁcient to achieve acceptable residuals
(Fig. 5e,f), conﬁrming a more complex binding process. In
contrast to the proposed binding of bungarotoxin42, where the
second step is concentration independent and most likely due to a
conformational adjustment, for VUF9432 the second step varies
with concentration, indicating the stepwise binding of the ligands.
Multiple binding of a ﬂuorescent aromatic molecule to
AChBP. We wondered whether different molecules could bind in
this manner and searched for planar aromatic molecules. AO43–45
is a ﬂuorescent planar aromatic molecule with increased solubility
compared with VUF9432. We found that AO (Fig. 6a) binds
the ligand-binding site of AChBP with micromolar afﬁnity
(pKi¼ 5.8, Fig. 6b). An analogue of AO, N-methylacridinium,
was shown to bind in the active site of the enzyme
acetylcholinesterase, which also displays afﬁnity for
acetylcholine46. When AO binding to Ac-AChBP was tested
using tryptophan ﬂuorescence quenching at high concentration,
we observed that as for VUF9432 the binding has a stoichiometric
ratio higher than one (Fig. 6c). In agreement with this, titration of
Ac-AChBP into an AO solution, Ac-AChBP quenched
AO ﬂuorescence at a stoichiometric ratio of 0.3 (Fig. 6d, black
dots). This quenching of AO by Ac-AChBP is inhibited in
the presence of an excess of nicotine, conﬁrming that AO is
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binding competitively to the binding pocket of Ac-AChBP
(Fig. 6d, grey dots).
The formation of the AO stack in Ac-AChBP should determine
differences in the emission spectra of the molecules as seen for
aromatic p–p stacking in organic aromatic cages47. The
ﬂuorescence spectra of AO in complex with Ac-AChBP
and those free in solution were compared. Emission at 525nm
(p–p* transition)43 of the complexed acridine moiety is quenched
in the presence of Ac-AChBP due to the interaction of AO with
the aromatic environment. During the titration the intensity at
525 nm increases without further shifts (Fig. 6f), as expected47.
AO is highly soluble allowing us to use isothermal titration
calorimetry (ITC) to follow its binding to AChBP. Our data
indicate that AO binds to Ac-AChBP with a stoichiometric ratio
of 3–4, with a Kd of 1.86 mM and that the sequential binding is
enthalpically favoured (Fig. 6g). Fitting of the experimental data
to a model indicates the existence of three events of AO binding
per ligand-binding domain of Ac-AChBP. This conﬁrms that
other planar molecules can bind to the Ac-AChBP ligand-binding
site in a similar manner to VUF9432. Interestingly, when AO was
tested in electrophysiology experiments on a7 nAChR-expressing
oocytes, it behaved as competitive inhibitor with an IC50 of
7.3 mM, showing an afﬁnity similar to the one measured for
Ac-AChBP (Fig. 6h). Thus, ligands with the potential
of supramolecular binding can be relevant for drug design on
nAChRs.
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Discussion
To our knowledge Ac-AChBP is the ﬁrst example of a target
protein binding a triple p–p stack of ligand molecules. In this
paper, we prove that Ac-AChBP binds VUF9432 (Figs 1–5),
fragments 2, 3, 4, and AO with stoichiometry higher than
one (Figs 4 and 6). All these compounds address the
canonical-binding site of Ac-AChBP and behave as competitive
binders (Figs 1, 4 and 6). Aromaticity and planarity of the
molecule positively inﬂuence the super-stoichiometry (Fig. 4 and
Supplementary Fig. S5).
VUF9432 is not very soluble and binds only weakly to a7
nAChR. When tested in electrophysiology experiments, we did
not observe any effect of VUF9432 on a7 nAChR expressed in
oocytes, probably due to the low solubility (data not shown).
However, we identiﬁed AO as a molecule that binds AChBP with
similar binding properties and stoichiometry. Interestingly,
this highly soluble ligand has robust inhibitory properties on
nAChR in oocytes, showing the potential for exploitation of these
types of ligand binding.
The crystal structure of VUF9432 in Ac-AChBP allows analysis
of the supramolecular binding mode. The three molecules of
VUF9432 stack in a parallel displaced orientation. The latter was
reported to be one of the lowest energetic conformations that
such a stack can acquire35. In addition several edge-to-face
interactions are observed, contributing to the binding properties.
The non-linearity of the binding curves of VUF9432,
compound 2–4 and AO, the stopped-ﬂow analysis of VUF9432
binding to Ac-AChBP and the ITC measurement of AO binding
to Ac-AChBP suggest that likely the stacking of the molecules is
happening in situ and not as preassembled stack (Figs 4–6).
However, we cannot exclude other scenarios. Stopped-ﬂow
ﬂuorescence measurement of the binding of a-bungarotoxin to
Ac-AChBP was shown to not be a one-step event43. This result
was interpreted, suggesting multiple binding modes of the toxin
to the binding site of Ac-AChBP. As postulated for the toxin also
a stack of VUF9432 could just bind preassembled and have
multiple binding modes.
Conformational search performed in gas phase would suggests
that this unusual stacking is not present for VUF9432 in solution
and that the assembly in situ at the protein-binding site would be
energetically more favoured. In particular, the dipole on
VUF9432 would disfavour the parallel stacking that is observed
for the distal and medial copies of the compound (Figs 1–3).
Hence, it is clear that interactions with Ac-AChBP could
contribute to stabilize these conﬁgurations and that each
VUF9432 molecule orients in the ligand-binding site according
to the electrostatic environment of the protein rather than their
individual local dipole moment.
Entropic factors hamper the intentional creation of parallel
p–p stacks of molecules. ‘Tweezer’ molecules have been used to
stabilize columns of aromatic molecules48. Also, reconstitution
of a discrete columnar stack of aromatic molecules has been
achieved using box-shaped coordination cage47. Here, we show
that a protein can enable the formation of a p–p stack of
molecules. The stacking is stabilized by the contribution of the
aromatic side chains of the ligand-binding site. Although p–p
interactions are thought to be weak35, they have been recognized
to have an important role in the folding and in the thermal
stability of proteins and the binding to ligands.
The binding site in Ac-AChBP is closely related to that of other
cys-loop receptors, where speciﬁcity for different ligands is
provided by amino-acid changes in the loops A–C and D–F. The
remarkable plasticity of the ligand-binding site, allowing the
binding of differently sized ligands in cys-loop receptors, is tuned
by the positioning of the C-loop and has a pivotal role in dictating
the dimension of the stack. Recently, Ac-AChBP was found to be
capable of accommodating two molecules of acetylcholine it its
binding sites, although relative occupancies are very different
between the two molecules49 (PDB: 2XZ5). Here, we show that
the binding site offers a variety of binding possibilities, by simple
repositioning of the C-loop (Figs 2 and 3) to accommodate either
one, two or three ligand molecules (Fig. 2), with relatively little
adjustment in the interactions.
The binding site AChBP was recently shown to accommodate
in situ Huisgen cycloaddiction ‘click’ reactions50. Thus, these
binding sites can serve as a reaction vessel for chemical reactions.
In combination with the ability to promote supramolecular self-
assembly, this binding site provides a unique environment for
novel chemistry, which can be further tuned by amino-acid
variations of loops A–F, varying the properties of the binding
pocket.
Multiple binding in a speciﬁc manner within a ligand-binding
site provides a novel paradigm for ligand binding. Aggregation of
molecules and the presence of multiple independent binding sites
have been discussed in the area of drug design previously51.
However, the interdependent binding required to make a ligand
stack is different. It provides speciﬁc opportunities as well as
novel challenges. Clearly, it will become important to take the
stacking possibility into account when analysing ligand binding.
Stoichiometry analysis will be important, in particular when
considering binding proﬁles that could potentially provide
this type of stacking. Meanwhile, one can see this as a novel
opportunity, providing previously unexplored avenues for drug
design. Not necessarily trivial, as large ﬂat molecules have obvious
disadvantages in design strategies compared with three-
dimensional fragments51, but deﬁnitely a new and unexplored
opportunity, where a ligand induces different opening of a ligand-
binding site while establishing the same interactions with the
target protein. In addition, the growing literature on ‘tweezer’
molecules48 and on biocatalytic induction of supramolecular
order52 may well prove helpful in exploring the possibilities
of purposely designing stacks of ligands in proteins.
Methods
Proteins. Untagged wild-type (wt) and mutants Ac-AChBPs were puriﬁed from
Sf21 insect cells as previously described19. The complementary DNAs for the
Ac-AChBP mutants, Ac-AChBP Y186A and Ac-AChBP Y193A, were generated
using Quik Change Mutagenesis following the manufacturer’s protocols. Mutant
proteins were expressed from baculovirus in Sf21 cells. SHS5Y neuroblastoma cell
membranes were used as source of a7 nAChR in radiodisplacement assays15.
Conformational search. A stochastic conformational search was performed using
MOE (version 2011.10, Chemical Computing Group Montreal, Canada), using
default settings.
Crystallization. The VUF9432-Ac-AChBP complex was formed by mixing the
protein at 3.5mgml 1 with 1mM VUF9432 and incubating on ice for 1 h.
Cocrystals were grown using the vapour diffusion method in a solution consisting
of 0.2M Li2SO4 and 0.8M ammonium sulphate in MMT buffer (pH 8.0) at 19 C.
Crystals were cryoprotected in mother liquor supplemented with 20% glycerol and
ﬂash-frozen in liquid nitrogen.
Structure solution and reﬁnement. Data were collected on beamline PX1 at the
SLS (Switzerland), and processed using iMOSFLM/SCALA software55. The
VUF9432-Ac-AChBP cocrystal was in space group P21 and diffracted to a
resolution of 2.4 Å. The structure was solved by molecular replacement using
PHASER53 and the Ac-ACHBP-HEPES structure (2BR7) (ref. 19) as model.
Iterative structure reﬁnement was performed using REFMAC54 from the CCP4
suite56 or BUSTER57. Non-crystallographic symmetry restraints (NCSR) were
maintained during reﬁnement, using local NCS restraints as implemented in
REFMAC or local structure similarity restraints in BUSTER. One TLS group per
chain was used in reﬁnement, and both the X-ray weight and B-factor restraint
weight were optimized using a local version of the PDB_REDO script58. Ligands and
water molecules were built in the ﬁnal stages of reﬁnement. Validation, performed
using molprobity59 and PDB_REDO, identiﬁed 0% of Ramachandran outliers and
2% of poor rotamers (overall score: 99th percentile). Distances, angles and buried
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surface areas were measured in Pymol (DeLano Scientiﬁc, LLC). Values and errors in
text refer to the average over the four ligand-binding sites with three ligands bound.
C-loop opening was calculated measuring the distance between Ne of W145 and Sg
of Cys 189. Tilting angles of aromatic planes was obtained by calculating the angle
between the normal to the planes and averaged over four ligand-binding sites.
Ligand radiodisplacement assays. Competition binding assays were performed
with Ac-AChBP (wt or mutants) in buffer (PBS, 20mM Tris, pH 7.4/0.05% Tween)
in a ﬁnal assay volume of 100 ml in Optiplates (PerkinElmer Life Science, Inc.,
USA). Ligands were added at 10 3–10 11M. Radioligand, [3H] epibatidine
(PerkinElmer, speciﬁc activity B56 Cimmol 1), was added at 2.25 nM. The
amount of protein was chosen such that we obtained a counting window in the
displacement curve of o5% of the total amount of radioligand, generally 2–20 ng.
Copper His-Tag PVT SPA beads (PerkinElmer) were added at 2mgml 1 ﬁnal
concentration. Plates were incubated at room temperature under continuous
shaking, protected from light, for 1.5 h. SPA beads were allowed to settle for 3 h in
the absence of light before counting. The label-bead complex was counted in a
Wallac Trilux 1450 Microbeta (PerkinElmer).
Binding assays with a-bungarotoxin-[125I] (IBTX) were performed as above at
1.8 nM IBTX.
Binding assays with the human a7 receptor were performed as above, but
without the SPA beads, as a ﬁltration assay. Human neuroblastoma cells (SH-
SY5Y) expressing human a7 nAChRs (from Christian Fuhrer, Department of
Neurochemistry, Brain Research Institute, Zurich) were cultured. The cells were
washed three times, and pelleted aliquots were stored frozen at –80 C. Before use
the cells were resuspended in ice-cold buffer and sonicated. [3H]MLA (American
Radiolabeled Chemicals, Inc., speciﬁc activity B100Cimmol 1) was used at a
ﬁnal concentration of 2 nM. Bound radioligand was collected on 0.3% poly-
ethyleneimine-pretreated Uniﬁlter-96 GF/C ﬁlters (PerkinElmer). Plates were
washed with ice-cold 50mM Tris buffer at pH 7.4. After drying the ﬁlters, scin-
tillation ﬂuid (MicroScint, PerkinElmer) was added and the radioactivity was
counted as above.
All radioligand binding data were evaluated by a non-linear, least-squares curve
ﬁtting procedure using GraphPad Prism (version 5, GraphPad Software, Inc., San
Diego, CA). All data are represented as mean±s.e.m. from at least three inde-
pendent experiments.
Trp and AO ﬂuorescence quenching. Ac-AChBP, 1mM in binding site, was
equilibrated with dilution of the ligands 1 h before ﬂuorescence measurement.
Equilibrium ﬂuorescence was monitored using a PheraStar ﬂuorescence plate
reader in the 96-well plates. Ac-AChBP was excited at 280 nm, and emission
intensity was monitored at 340 nm with an emission slit of 8 nm. AO was excited at
495 nm and emission monitored at 525 nm with an emission slit of 10 nm.
Data were normalized, and pKi values were calculated by ﬁtting to a sigmoidal
dose–response curve with GraphPad.
To determine ligand stoichiometries, Ac-AChBP (20mM in binding site) was
titrated with increasing concentration of ligand until o8% quenching was
apparent. A straight line was ﬁt through the average of the plateau points. For
AO titration by Ac-AChBP, AO (100 mM) was titrated with increasing con-
centration of protein. When indicated 1mM nicotine was added to the assay to
compete with AO. Full ﬂuorescence spectra were recorded with a QuantaMaster
3 Fluorometer.
Isothermal calorimetry. ITC experiments were performed on a VP-ITC
microcalorimeter (Microcal) at 25as described17. Ac-AChBP used in these
experiments was dialysed in PBS, and the AO was solubilized in the same buffer.
For a typical experiment, the ligand at a concentration of 0.5mM was titrated into
20mM Ac-AChBP. Titration of ligand in buffer alone was performed to determine
the change in enthalpy caused by the dilution of the ligand and subtracted as
background from the actual ligand-binding experiment. Corrected data were
analysed using software supplied by the manufacturer and ﬁtted using a non-linear
least-squares method to a model describing one set of binding sites.
Stopped-ﬂow kinetics. Stopped-ﬂow measurement were obtained using a TgK
Scientiﬁc stopped-ﬂow system (model SF-61DX2). Ac-AChBP was excited at
280 nm, and emission was recorded with a band ﬁlters WG320 and VG11. Changes
in ﬂuorescence emission intensity were ﬁt to a ﬁrst- (nicotine) or a second-
(VUF9432) order equation.
Electrophysiology. To probe effects of VUF9432 and AO at the a7 nAChR
receptors, experiments were conducted at Xenopus oocytes expressing the homo-
meric human a7 nAChRs. Expression was obtained by intranuclear injection of
10 nl of a solution containing the cDNA encoding for the human a7 subunit at a
concentration of 0.2 mgml 1 using an automated injector (roboinject, Multi-
channelsystems, Germany). Oocyte preparation and injection was done using the
standard procedures as previously described60. Three or more day later,
electrophysiological properties of the cells were assessed using an automated
electrophysiological setup (HiClamp, Multichannelsystems, Germany). Recordings
electrodes were ﬁlled with 3M KCl and oocytes superfused with OR2 medium
containing in mM: NaCl 82.5, KCl 2.5, HEPES 5, CaCl2.2H2O 1.8, MgCl2.6H2O 1,
pH 7.4. Cells were held at  80mV, and a7 expression was tested responses by a
brief exposure to 1mM acetylcholine. Cells displaying robust currents were
subsequently tested for their sensitivity to the compound.
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